Results 11 to 20 of about 2,492,664 (191)

CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells

International Journal of Nanomedicine, 2016
Shuang Jiang,1,2,* Xiaobo Wang,2,* Zhiran Zhang,2 Lan Sun,3 Yunzhu Pu,3 Hongjuan Yao,3 Jingcao Li,3 Yan Liu,3 Yingge Zhang,3 Weijing Zhang1,4 1Department of Lymphoma, Affiliated Hospital of the Military Medical Academy of Sciences, Beijing, 2Department ...
Jiang S, Wang X, Zhang Z, Sun L, Pu Y, Yao H, Li J, Liu Y, Zhang Y, Zhang W   +9 more
doaj   +1 more source

Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment

Scientific Reports, 2020
Lymphoma is the most common hematological cancer in dogs. Canine diffuse large B cell lymphoma shows a relatively good response to treatment with multi-agent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy; however, the 2 ...
Takuya Mizuno, Yukinari Kato, Mika K. Kaneko, Yusuke Sakai, Toshinori Shiga, Masahiro Kato, Toshihiro Tsukui, Hirofumi Takemoto, Akio Tokimasa, Kenji Baba, Yuki Nemoto, Osamu Sakai, Masaya Igase   +12 more
doaj   +2 more sources

Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series [PDF]

Frontiers in Immunology
IntroductionAnti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and ...
Regina Berkovich, Jonathan Calkwood, Heidi Crayton, April Erwin, Simon Faissner, Ralf Gold, Joshua Katz, Mark Leekoff   +7 more
doaj   +2 more sources

Probing the sensitivity of autoantibody production to B cell depletion by Rituximab [PDF]

, 2010
Rituximab, a monoclonal antibody directed against the human CD20 antigen, causes profound depletion of all B cells. When used in patients with autoimmune disease, IgG autoantibody titres often fall whilst serum IgG anti-tetanus toxoid antibody titres are
Ferraro, Alastair James
core   +7 more sources

Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment [PDF]

European Medical Journal Oncology, 2013
Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of different haematological cancers with a wide range of aggressiveness. NHLs represent >80% of lymphomas and the majority of NHLs involve B cells.
Letizia Polito, Massimo Bortolotti, Stefania Maiello, Maria Giulia Battelli, Andrea Bolognesi   +4 more
doaj   +1 more source

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies [PDF]

Current Opinion in Immunology, 2008
The anti-CD20, B-cell-specific mAb rituximab (RTX) has been approved for treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis. Under conditions of high B cell burden, exhaustion of the body's effector mechanisms, for example, NK-cell-mediated killing, may lead to substantial decreases in the immunotherapeutic efficacy of this mAb ...
Ronald P, Taylor, Margaret A, Lindorfer
openaire   +2 more sources

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach

International Journal of Infectious Diseases, 2021
Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response, causing severe manifestations during COronaVIrus Disease-2019 (COVID-19).
Alessandra D’Abramo, Serena Vita, Gaetano Maffongelli, Andrea Mariano, Chiara Agrati, Concetta Castilletti, Delia Goletti, Giuseppe Ippolito, Emanuele Nicastri   +8 more
doaj   +1 more source

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

Haematologica, 2011
Background Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.
Mounia Sabrina Braza, Bernard Klein, Geneviève Fiol, Jean-François Rossi   +3 more
doaj   +1 more source

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia

Leukemia Research Reports, 2022
Monoclonal antibodies have established an important role in the treatment armamentarium of hematological malignancies, including Waldenström's macroglobulinemia.
Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis   +2 more
doaj   +1 more source

The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies

Virulence, 2022
The optimal interval before receiving SARS-COV-2 vaccination for patients who have received anti-CD 20 monoclonal antibodies remains unclear. We considered original studies up to 29 October 2022 and conducted searches in Embase,Medrxiv, PubMed, and SSRN.
Kexin Liu, Jinyu Li, Gaosi Xu
doaj   +1 more source